SCHEMBL10071961

SCHEMBL10071961

O=C(CNCCCc1ccccc1)c1ccc(O)c(O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.52
ADORA3 P0DMS8 1/20 0.52
CHRM1 P11229 1/20 0.52
ADRA2B P18089 1/20 0.52
ADRA2C P18825 1/20 0.52
DRD1 P21728 1/20 0.52
SLC6A2 P23975 1/20 0.52
SLC6A4 P31645 1/20 0.52
ADRA1A P35348 1/20 0.52
PTGS2 P35354 1/20 0.52
HRH1 P35367 1/20 0.52
DRD3 P35462 1/20 0.52
OPRK1 P41145 1/20 0.52
SLC6A3 Q01959 1/20 0.52
PDE4D Q08499 1/20 0.52
KCNH2 Q12809 1/20 0.52
HRH3 Q9Y5N1 1/20 0.52
ALOX15 P16050 2/20 0.50
IGF1R P08069 1/20 0.50
TRPV1 Q8NER1 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9768036 0.92 PTGS2 (0.55) ADRB2ADORA3CHRM1ADRA2BADRA2C
SCHEMBL11482367 0.84 NPC1 (0.61) SIGMAR1NPC1RAB9AHPGDKDM4E
SCHEMBL10674580 0.80 NPC1 (0.69) NPC1RAB9AALDH1A1MAPTHPGD
SCHEMBL9768141 0.80 ALPL (0.48) PTGS2TRPV1HDAC1MAPTHSD17B10
SCHEMBL11271218 0.80 HDAC1 (0.45) ADRB2ADORA3CHRM1ADRA2BADRA2C
Acetic Acid SCHEMBL22551315 0.79 ALPL (0.46) PTGS2HDAC1MAPTKDM4EMEN1
Formic Acid SCHEMBL22551318 0.79 MMP1 (0.46) PTGS2ALOX15HDAC1RAB9AALDH1A1
Formic Acid SCHEMBL30892158 0.79 MMP1 (0.46) PTGS2ALOX15HDAC1RAB9AALDH1A1
Hydrochloric Acid SCHEMBL11277285 0.78 HDAC1 (0.44) ADRB2ADORA3CHRM1ADRA2BADRA2C
SCHEMBL9768043 0.78 TRPV1 (0.49) ALOX15TRPV1HDAC1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9266817-B2 Catecholamine derivatives for obesity and neurological disorders EMORY UNIVERSITY (US) 2016-02-23 US disclosed
US-20140329907-A1 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-11-06 US disclosed
US-20120022086-A1 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS EMORY UNIVERSITY (US) 2012-01-26 US disclosed
WO-2010107866-A2 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS EMORY UNIVERSITY (US) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022086-A1 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS BDNF, NTRK2, COMT ADRB2 53/4885ADORA3 96/4885CHRM1 380/4885
US-20140329907-A1 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS BDNF, NTRK2, COMT ADRB2 53/4885ADORA3 96/4885CHRM1 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.